Entries |
Document | Title | Date |
20080213303 | MUTANT FORMS OF CHOLERA HOLOTOXIN AS AN ADJUVANT - Mutant cholera holotoxins comprising a cholera toxin subunit A having single amino acid substitutions in the amino acid positions 16 or 72 or a double amino acid substitution in the amino acid positions 16 and 68 or 68 and 72 have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in immunogenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule. | 09-04-2008 |
20080254061 | Mycobacteria Expressing Hiv-1 and Malaria Antigens - Provided are recombinant mycobacteria expressing an HIV-1 antigen and a malarial antigen. Also provided are | 10-16-2008 |
20080254062 | USE OF AN AVIRULENT BORDETELLA MUTANT AS A LIVE VACCINE VECTOR - The present invention pertains to | 10-16-2008 |
20080260776 | Preparation of Salmonella Broad-Spectrum Vaccines - The present invention relates to a pharmaceutical composition providing protective unity against a broad spectrum of | 10-23-2008 |
20080274136 | Polyvalent Attenuated Live Vaccine For Preventing and Curing Vibriosis of Cultivated Fish - A novel polyvalent attenuated live bacterial vaccine for preventing and curing vibriosis of cultivated fish is provided. The vaccine mainly comprises attenuated deletion strain of | 11-06-2008 |
20080292656 | Combination of a Bacterial Cell and a Biologically Active Agent - The present invention is related to a combination comprising a first constituent and a second constituent, wherein the first constituent is a bacterial cell which comprises at least one recombinant nucleic acid molecule encoding a phagolysosomal escape peptide or polypeptide; and wherein the second constituent is a biologically active agent. In certain embodiments, the combination is of use as a vaccine to induce an immune response in a mammal. | 11-27-2008 |
20090017061 | Mycobacteria with Mannose Cap-Deficient Lipoarabinomannan - The present invention relates to mycobacterial lipoarabinomannan cap-specific mannosyl transferases and nucleic acid encoding such transferases. The invention further relates to | 01-15-2009 |
20090035328 | fHbp- AND LPXL1-BASED VESICLE VACCINES FOR BROAD SPECTRUM PROTECTION AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS - The present invention generally provides methods and compositions for eliciting an immune response against | 02-05-2009 |
20090068222 | METHODS TO INCREASE TRANSGENE EXPRESSION FROM BACTERIAL-BASED DELIVERY SYSTEMS BY CO-EXPRESSING SUPPRESSORS OF THE EUKARYOTIC TYPE I INTERFERON RESPONSE - Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene. | 03-12-2009 |
20090074811 | KENNEL COUGH VACCINE - Improved, low cost vaccines for administration to living subjects such as mammals and birds are provided, which include killed recombinantly modified microorganisms (whole cell recombinant bacterin vaccine), the latter including recombinant DNA encoding at least one protective protein (e.g., an antigenic protein) which has been expressed by the microorganisms prior to killing thereof. The protective protein(s) are operable to prevent or reduce the severity of a disease of the subject. The vaccine preparations of the invention do not require separation of the protective protein(s) from the host recombinant microorganism(s), thereby materially decreasing the complexity and cost of the vaccine formulations. A preferred vaccine against kennel cough includes recombinantly modified microorganisms which express protective antigens containing pertactin and filamentous hemagglutinin protein products. | 03-19-2009 |
20090081250 | Compositions and methods for treatment of cervical cancer - The present invention provides methods of treating, protecting against, and inducing immune response against cervical cancer, comprising the step of administering to a sub recombinant | 03-26-2009 |
20090110696 | Mycobacterial SecA2 Mutants - Provided are mycobacteria comprising (a) a mutation that is not in a SecA2 gene that attenuates the virulence of the mycobacteria in a mammalian host, and (b) a mutation in a SecA2 gene that eliminates SecA2 activity. Also provided are mycobacteria that comprise a mutation in a SecA2 gene that eliminates SecA2 activity, where the mycobacteria are not | 04-30-2009 |
20090117151 | VECTOR FOR ANTI-HPV VACCINE AND TRANSFORMED MICROORGANISM BY THE VECTOR - Expression vectors that can efficiently produce virion capsid protein, tumor-associated protein of human papillomavirus on a microbial surface. Bacterial strains harboring such surface display vectors, and the use of the bacterial strains or their extracts or purified products as complex vaccines, are also described. The surface display vectors contain one or more than two genes selected from among pgsB, pgsC and pgsA, encoding a poly-χ-glutamic acid synthetase complex (pgsBCA) of a | 05-07-2009 |
20090123492 | GENERATION OF NEW BCG VACCINE STRAINS PROTECTING AGAINST THE ESTABLISHMENT OF LATENT MYCOBACTERIUM TUBERCULOSIS INFECTION AND REACTIVATION FROM THE LATENT OR PERSISTENT STATE - A vaccine for treating or preventing the establishment of latent tuberculosis infections is provided. The vaccine comprises a recombinant | 05-14-2009 |
20090136542 | Immunogenic composition and method of developing a vaccine based on portions of the HIV matrix protein - The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one covalent binding site of myristate (SEQ ID NOS: 1-3) on the HIV matrix protein. The present invention contemplates three categories of embodiments: protein or protein fragments (SEQ ID NO: 1), messenger RNA, or DNA/RNA (SEQ ID NOS:2-3). DNA/RNA compositions may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants. | 05-28-2009 |
20090148473 | MICROBIAL VACCINE AND VACCINE VECTOR - The present invention includes cold-adapted, acid-fast bacterium for use as a vaccine and a vaccine vector. In preferred embodiments, the cold-adapted, acid-fast bacterium is a | 06-11-2009 |
20090155304 | Modified Cyanovirin-N Polypeptide - This disclosure relates to a modified version of cyanovirin-N protein and a transformed | 06-18-2009 |
20090169582 | RECOMBINANT LACTOBACILLUS AND USE OF THE SAME - The invention relates to recombinant | 07-02-2009 |
20090175901 | IMMUNOSTIMULATORY RECOMBINANT INTRACELLULAR PATHOGEN IMMUNOGENIC COMPOSITIONS AND METHODS OF USE - Immunogenic compositions comprising recombinant intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens and immunostimulatory molecules are provided. Exemplary immunogenic compositions include, but are not limited to, recombinant BCG expressing Mycobacteria major extracellular proteins and immunostimulatory molecules. | 07-09-2009 |
20090202586 | ATTENUATED VACCINE FOR TULAREMIA | 08-13-2009 |
20090202587 | COMPOSITIONS COMPRISING HMW-MAA AND FRAGMENTS THEREOF, AND METHODS OF USE THEREOF - This invention provides recombinant polypeptides comprising a fragment of a High Molecular Weight Melanoma-Associated Antigen (HMW-MAA), recombinant | 08-13-2009 |
20090220540 | Helicobacter System and Uses Thereof - based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, | 09-03-2009 |
20090246222 | Live Attenuated Bordetella Strains as a Single Dose Vaccine Against Whooping cough | 10-01-2009 |
20090263418 | MEANS AND METHODS FOR MANIPULATING SEQUENTIAL PHAGOLYSOMALCYTOSOLIC TRANSLOCATION OF MYCOBACTERIA, AND USES THEREOF - Mycobacteria such as | 10-22-2009 |
20090263419 | Live attenuated bacterial vaccine - A live, attenuated bacterium of the genus | 10-22-2009 |
20090297556 | Salmonella Based Oral Vaccines for Anthrax - A vaccine for the prevention of anthrax, including a live, attenuated | 12-03-2009 |
20090324638 | LIVE BACTERIAL VACCINE - The present invention relates, e.g., to a | 12-31-2009 |
20100008949 | VACCINE FOR PORCINE POST-WEANING DIARRHEA CAUSED BY ENTEROTOXIGENIC ESCHERICHIA COLI - Vaccines and methods for making and using the same. An example vaccine may be a vaccine against enterotoxigenic | 01-14-2010 |
20100008950 | COMPOSITION AND METHOD FOR THE INDUCTION OF IMMUNITY AGAINST BACILLUS CEREUS GROUP BACTERIA - A composition comprised of one or more bacterial proteins that are conserved among members of | 01-14-2010 |
20100028378 | TOXIN-ANTITOXIN SYSTEM AND APPLICATIONS THEREOF - The present invention relates to the discovery of a toxin-antitoxin system in opportunistic human pathogen | 02-04-2010 |
20100040648 | PLASMIDS WITH IMMUNOLOGICAL ACTION - Recombinant plasmids usable for the transfection of eukaryotic and prokaryotic cells are described; such plasmids have a length comprised between 7 and 12 kbases and comprise a sequence encoding the heavy chain of an immunoglobulin; in particular, they may be used:
| 02-18-2010 |
20100055127 | Procedure For Expressing A Tbpb Protein On The Bacterial Surface Of An Attenuated Oral Live Vaccine As Prototype Of A Meningitis B Vaccine - A procedure for obtaining the expression of a membrane antigen of a pathogen against which an live oral vaccine development is desirable on the surface of a negative Gram bacteria to which virulence is attenuated, or another bacteria or other Gram negative or positive bacteria with probiotic features which are compatible with the proposed expression system and that can be used as a live oral vaccine, wherein a plasmid is constructed and obtained based on the structure of pET family plasmids, with tbpB gene incorporated under the control of T7 promoter or another equivalent one, with the addition of a metabolic marker in the plasmid vector, previously cloned with its own promoter, inactivating, at the same time, the antibiotic resistance. In addition, recombinant microorganism such as an attenuated vaccine strain against group B meningitis with immunizing and protective properties against infection by | 03-04-2010 |
20100092511 | ESCHERICHIA COLI MUTANTS AND METHODS OF USE THEREOF - The present invention provides methods and compositions for production of gram-negative bacterial mutants that are defective in intestinal colonization capacity and sensitive to infection by bacteriophage P1. Thus the present invention provides immunogenic compositions for the prevention or attenuation of food- and water-borne illnesses associated with ingestion of bacteria such as enterohemorrhagic | 04-15-2010 |
20100124558 | REGULATED EXPRESSION OF ANTIGEN AND/OR REGULATED ATTENTUATION TO ENHANCE VACCINE IMMUNOGENICITY AND/OR SAFETY - The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest. | 05-20-2010 |
20100129396 | V. CHOLERAE HYPEREXPRESSING RECOMBINANT CHOLERA TOXIN B SUBUNIT SHOWING DUAL IMMUNOGENICITY - Oral immunogenic compositions imparting dual protection against enterotoxigenic labile toxin (LT)-expressing | 05-27-2010 |
20100136048 | LIVE BACTERIAL VACCINES RESISTANT TO CARBON DIOXIDE (CO2), ACIDIC PH AND/OR OSMOLARITY FOR VIRAL INFECTION PROPHYLAXIS OR TREATMENT - The present invention relates to gram-negative bacterial mutants resistant to one or more stress conditions, including, but not limited to, CO | 06-03-2010 |
20100260794 | LIVE ATTENUATED SALMONELLA VACCINE - The present invention relates to attenuated guaB deletion mutants of a bacterium infecting veterinary species, more in particular | 10-14-2010 |
20100266627 | ALLELIC EXCHANGE MUTAGENESIS IN MAP - Particular aspects provide efficient allelic exchange methods to generate directed mutations within genes of slow-growing stains of mycobacteria (e.g., | 10-21-2010 |
20100272748 | VACCINE FOR PROTECTION AGAINST SHIGELLA SONNEI DISEASE - Compositions and methods for protecting a susceptible host against an infection of | 10-28-2010 |
20100291140 | ANTIBIOTIC RESISTANCE FREE LISTERIA STRAINS AND METHODS FOR CONSTRUCTING AND USING SAME - The present invention provides | 11-18-2010 |
20100316668 | IMMUNOTHERAPY FOR PROSTATE CANCER USING RECOMBINANT BACILLE CALMETTE-GUERIN EXPRESSING PROSTATE SPECIFIC ANTIGENS - The present invention relates to the treatment of prostate cancer. Methods and compositions comprising recombinant BCG are provided for eliciting potent immune responses against prostate specific antigens that are effective for treatment of prostate cancer and metastatic disease. | 12-16-2010 |
20100330116 | LIVE ATTENUATED SALMONELLA FOR USE AS VACCINE - The present invention relates to live attenuated | 12-30-2010 |
20110027309 | COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES - Provided herein are | 02-03-2011 |
20110064765 | PCV-2 VACCINE - The present invention relates to a vaccine against porcine circovirus type 2 (PCV-)2 and a method for the manufacture of such a vaccine, for protecting piglets against PCV-2 infection. It has been found that a vaccine comprising at least 20 microgram/dose of ORF-2 protein of porcine circovirus type 2 (PCV-2 is capable of eliciting a protective immune response against PCV-2 (and thus against PMWS) even when they have a relatively high titer of MDA against PCV-2. | 03-17-2011 |
20110064766 | Attenuated Vaccine Against Fish Pathogen Francisella Sp. - An attenuated bacteria has been made by an insertion mutation in the iglC gene of | 03-17-2011 |
20110104200 | Methods, compositions and kits for vegetative cell-based vaccines and spore-based vaccines - Methods for immunizing a subject to an antigen of an infectious agent, a tumor, or an allergen are provided, using vegetative cytoplasmic expression of the antigen or spore surface display of the antigen, and contacting the subject with a composition including a spore or a vegetative cell or both with or without an adjuvant. Also included are thermally-stable vaccine compositions using the method described above and kits including the compositions. | 05-05-2011 |
20110123565 | Structural Proteins of Fish Pancreatic Disease Virus and Uses Thereof - The present invention relates to the structural proteins of the causative agent of Pancreatic Disease in fish, nucleotide sequences encoding said proteins, vaccines comprising said proteins or nucleotide sequences and diagnostic kits comprising said proteins or nucleotide sequences. | 05-26-2011 |
20110129492 | Immunostimulatory Recombinant Intracellular Pathogen Immunogenic Compositions and Methods of Use - Immunogenic compositions comprising recombinant intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens and immunostimulatory molecules are provided. Exemplary immunogenic compositions include, but are not limited to, recombinant BCG expressing | 06-02-2011 |
20110171251 | Piscirickettsia salmonis antigens and use thereof - The present invention discloses novel proteins, e.g., antigens, from | 07-14-2011 |
20110171252 | Streptococcus suis vaccines and diagnostic tests - Described are | 07-14-2011 |
20110189225 | ATTENUATED BACTERIA USEFUL IN VACCINES - The invention provides strains of bacteria, especially enterotoxigenic | 08-04-2011 |
20110200634 | IMMUNOGENIC FORMULATION - The present invention describes an immunogenic formulation to be used in mammals against the respiratory syncytial virus (RSV), consisting in the Calmette-Guérin bacillus (BCG) strain or other attenuated | 08-18-2011 |
20110229515 | IDENTIFICATION OF GENES - A method for identifying a microorganism having a reduced adaptation to a particular environment comprising the steps of:
| 09-22-2011 |
20110262480 | Method for producing multiple modifications in the chromosome of gram-negative bacteria and salmonella strains which are deficient in c-di-GMP synthesis obtained by said method - Method for producing multiple modifications in the chromosome of Gram-negative bacteria and | 10-27-2011 |
20110268760 | SALMONELLA VECTORED VACCINES AGAINST CHLAMYDIA AND METHODS OF USE - The invention provides an attenuated Salmonella vaccine vector comprising one or more heterologous polynucleotides that encode immunogenic Chlamydial peptides. In one embodiment, the attenuated Salmonella vaccine vector comprises aroC and ssaV attenuating mutations. The heterologous polynucleotides encoding the immunogenic Chlamydial peptides can be under the control of an inducible promoter such as a Salmonella ssaG promoter. In one embodiment of the invention, the immunogenic Chlamydial peptide is a PmpG peptide, for instance, a CT110, CT84 or CT40 peptide. | 11-03-2011 |
20110274719 | HELICOBACTER SYSTEM AND USES THEREOF - based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, | 11-10-2011 |
20110287052 | RECOMBINANT BACTERIUM CAPABLE OF ELICITING AN IMMUNE RESPONSE AGAINST STREPTOCOCCUS PNEUMONIAE - The invention encompasses a recombinant bacterium capable of eliciting an immune response against | 11-24-2011 |
20110305724 | IMMUNOTHERAPEUTIC, ANTI-TUMORIGENIC COMPOSITIONS AND METHODS OF USE THEREOF - This invention relates to immunotherapeutic vaccine composition comprising an ISG15 tumor antigen and to methods of preventing and treating a tumor growth by using said immunotherapeutic composition. | 12-15-2011 |
20120020996 | VACCINES AGAINST CLOSTRIDIUM DIFFICILE AND METHODS OF USE - Attenuated microorganisms expressing | 01-26-2012 |
20120027794 | TUBERCULOSIS VACCINE WITH IMPROVED EFFICACY - The present invention relates to novel recombinant vaccines providing protective immunity against tuberculosis. Further, the present invention refers to novel recombinant nucleic acid molecules, vectors containing said nucleic acid molecules, cells transformed with said nucleic acid molecules and polypeptides encoded by said nucleic acid molecules. | 02-02-2012 |
20120039931 | DNA COMPOSITION ENCODING AN IMMUNOGENIC VEGF RECEPTOR PEPTIDE AND METHODS OF USE THEREOF - A method of inhibiting endothelial cell proliferation in a mammal is provided. The method comprises the step of administering to the mammal an effective immunological response eliciting amount of a DNA composition comprising a DNA construct operably encoding a VEGF receptor polypeptide and a pharmaceutically acceptable carrier therefor, whereby said mammal exhibits an immune response elicited by vaccine and specific to proliferating endothelial cells. The methods of this invention inhibit vascular endothelial cell proliferation in the tumor micro-environment. Angiogenesis inhibition and subsequent decrease in tumor growth and dissemination is achieved. | 02-16-2012 |
20120058142 | VACCINE FOR PROTECTION AGAINST SHIGELLA SONNEI DISEASE - Compositions and methods for protecting a susceptable host against an infection of | 03-08-2012 |
20120064114 | USE OF E. COLI SURFACE ANTIGEN 3 SEQUENCES FOR THE EXPORT OF HETEROLOGOUS ANTIGENS - The present invention provides an export signal system based on | 03-15-2012 |
20120100177 | SALMONELLA ENTERICA PRESENTING C. JEJUNI N-GLYCAN OR DERIVATIVES THEREOF - The present invention relates to | 04-26-2012 |
20120121643 | Engineered listeria and methods of use thereof - The invention provides a bacterium containing a polynucleotide comprising a nucleic acid encoding a heterologous antigen, as well as fusion protein partners. Also provided are vectors for mediating site-specific recombination and vectors comprising removable antibiotic resistance genes. | 05-17-2012 |
20120135033 | MULTIPLE DELIVERY SYSTEM FOR HETEROLOGOUS ANTIGENS - The invention is directed to an episomal recombinant nucleic acid encoding at least two heterologous antigens each fused to a PEST-endogenous polypeptide, vaccines comprising the same, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering the same. | 05-31-2012 |
20120177682 | Helicobacter System and Uses Thereof - based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, | 07-12-2012 |
20120282293 | Multivalent Live Vector Vaccine against Clostridium difficile-Associated Disease - The invention relates to a multivalent | 11-08-2012 |
20120321662 | Methods of Eliciting or Boosting a Cellular Immune Response - Site-specific | 12-20-2012 |
20130004537 | BACTERIUM COMPRISING A REGULATED rfaH NUCLEIC ACID - The present invention encompasses a recombinant bacterium comprising a regulated rfaH nucleic acid, as well as a vaccine comprising said recombinant bacterium. Other embodiments of the present invention encompass a recombinant bacterium comprising a regulated rfaH nucleic acid and a regulated rfc nucleic acid, while additional embodiments encompass a recombinant bacterium comprising a regulated rfaH nucleic acid and at least one nucleic acid encoding at least one exogenous antigen. | 01-03-2013 |
20130078274 | LIVE, ORAL VACCINE FOR PROTECTION AGAINST SHIGELLA DYSENTERIAE SEROTYPE 1 - The invention relates to | 03-28-2013 |
20130122039 | V. Cholera hypereexpressing recombinant cholera toxin B subunit showing dual immunogenicity - Immunogenic compositions imparting dual protection against enterotoxigenic labile toxin (LT)-expressing | 05-16-2013 |
20130156809 | Recombinant Bacterium and Uses Thereof - The present invention relates to a recombinant bacterium expressing an antigen that is translocated to the cytosol of a host organism, and uses thereof. To this end, the present invention provides a recombinant bacterium comprising a nucleic acid encoding an antigen that is translocated to the cytosol of a host cell utilizing Type III secretion system. The recombinant bacterium is generally chosen from intracellular pathogens that reside in the phagosome and fail to induce rapid T cell activation. The translocated antigen may be a viral antigen, a bacterial antigen, or a tumour antigen. Methods of imparting immunity using the recombinant bacterium are also provided. | 06-20-2013 |
20130171190 | REGULATED EXPRESSION OF ANTIGEN AND/OR REGULATED ATTENTUATION TO ENHANCE VACCINE IMMUNOGENICITY AND/OR SAFETY - The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest. | 07-04-2013 |
20130177589 | VACCINES COMPRISING HEAT-SENSITIVE TRANSGENES - The present disclosure provides temperature sensitive essential nucleic acid molecules from a psychrophilic bacterium, proteins encoded by the nucleic acid molecules, as well as recombinant cells into which have been introduced such nucleic acid molecules. The disclosed recombinant cells containing one or more essential nucleic acid molecules from a psychrophilic bacterium are thereby made temperature sensitive, and can be administered to a mammal to induce an immune response in the mammal. | 07-11-2013 |
20130183336 | Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology - The present invention relates to a life attenuated | 07-18-2013 |
20130224242 | Methods To Increase Transgene Expression From Bacterial-Based Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response - Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene. | 08-29-2013 |
20130230555 | SYNTHETIC LIPID BIOLOGY FOR COMBINATORIAL ENGINEERING OF ENDOTOXIN - The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure relates to genetic engineering of Gram-negative bacteria expressing different species of lipid A on their surface. In one embodiment, the present disclosure provides for an engineered strain of | 09-05-2013 |
20130243814 | MICROBIAL DELIVERY SYSTEM - The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies and thereby reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity. | 09-19-2013 |
20130315950 | METHODS AND COMPOSITIONS USING LISTERIA FOR ADJUVANT TREATMENT OF CANCER - Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active | 11-28-2013 |
20140044749 | VACCINES AGAINST CLOSTRIDIUM DIFFICILE AND METHODS OF USE - Attenuated microorganisms expressing | 02-13-2014 |
20140072595 | GENE EXPRESSION AND ERADICATION SYSTEM IN HELICOBACTER PYLORI - The present invention relates to a gene expression and eradication system for | 03-13-2014 |
20140093534 | COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES - Provided herein are | 04-03-2014 |
20140120134 | LIVE, ORAL VACCINE FOR PROTECTION AGAINST SHIGELLA DYSENTERIAE SEROTYPE 1 - The invention relates to | 05-01-2014 |
20140186392 | Interferon- Production Modulating Listeria Strains and Methods for Using Same | 07-03-2014 |
20140212454 | PREVENTION OF SALMONELLA RECRUDESCENSE - The present invention relates to novel | 07-31-2014 |
20140212455 | RECOMBINANT BCG STRAINS WITH ENHANCED ABILITY TO INHIBIT INTRACELLULAR MYCOBACTERIAL GROWTH - A recombinant bacterial cell strain is disclosed. It comprises: a) a first vector comprising a fusion transgene encoding Ag85B-CFP10 fusion protein, the fusion transgene being operably linked to a promoter effective for expression of the Ag85B-CFP10 fusion protein; and b) a second vector comprising a transgene encoding interleukin-12 (IL-12), the transgene being operably linked to a promoter effective for expression of the IL-12 protein. A method of inhibiting intracellular growth of | 07-31-2014 |
20140220072 | SHIGELLA-DERIVED VECTOR AND METHODS OF USING THE SAME - Recombinant vectors comprising the cell entry region of the | 08-07-2014 |
20140234369 | LIVE-ATTENUATED COMPOSITIONS FOR BACTERIAL INFECTIONS - The present invention relates to compositions and methods for disease treatment and prevention through administration of a live attenuated composition. In particular, the present invention provides compositions and methods for the treatment and prevention of urinary tract infection by administration of a live attenuated compositions lacking O-antigen ligase activity. | 08-21-2014 |
20140234370 | COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS - This invention provides compositions and methods for treating and vaccinating against a Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a human subject. | 08-21-2014 |
20140234371 | MODIFIED GRAM POSITIVE BACTERIA AND USES THEREOF - The present invention relates to a gram positive bacterium, preferably a lactic acid bacterium (LAB) or | 08-21-2014 |
20140242111 | Engineered Bacteria for Oral Delivery of Glucoregulatory Proteins - Disclosed is an oral delivery system that overcomes major barriers encountered in the gastrointestinal tract, particularly rapid proteolytic degradation and low intestinal permeability. Provided is a method for oral delivery of an engineered microorganism to a mammal where the microorganism produces a macromolecule having a desired bioavailability outcome. | 08-28-2014 |
20140248309 | DNA PROMOTERS AND ANTHRAX VACCINES - The invention is related to intracellularly induced bacterial DNA promoters and vaccines against | 09-04-2014 |
20140322266 | INDUCTION OF MUCOSAL TOLERANCE TO ANTIGENS - The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of Foxp3 | 10-30-2014 |
20140335125 | ATTENUATED AND ADAPTED STRAIN OF PSEUDOMONAS FOR DELIVERING ANTIGENS - A process for obtaining an adapted strain of | 11-13-2014 |
20140363465 | MYCOBACTERIAL VACCINE VECTORS AND METHODS OF USING THE SAME - Mycobacterium bovis BCG is a potent stimulator of the cellular immune response and has potential as a recombinant vaccine vector. Disclosed are BCG strains that generate greater MHC class I presentation of a transgenic protein, relative to the unmutated parental strain, and that improve a recipient's CD8+ T cell response against the transgenic protein following vaccination. The mycobacterial constructs and their respective t/ansposon mutant BCG strains exhibit increased immunogenicity that is several times greater than responses generated by the parental strain and other existing modified rBCG strains. Furthermore, upon introducing the SIV gag gene into these novel strains, we observed that these strains primed for increased CD8+ T cell responses in a heterologous prime/boost regimen, comparable to levels generated by plasmid DNA vaccines. Creation of a second generation rBCG vector that may be utilized as a vaccine vector for immunizing against a variety of pathogens. | 12-11-2014 |
20150017204 | LIVE BACTERIAL VACCINES RESISTANT TO CARBON DIOXIDE (CO2), ACIDIC PH AND/OR OSMOLARITY FOR VIRAL INFECTION PROPHYLAXIS OR TREATMENT - The present invention relates to gram-negative bacterial mutants resistant to one or more stress conditions, including, but not limited to, CO | 01-15-2015 |
20150037369 | Methods of Transforming a Listeria - Site-specific | 02-05-2015 |
20150044256 | Oral Vaccine For Borrelia - The present invention relates to vaccines for control of | 02-12-2015 |
20150056246 | SUBUNIT VACCINE DELIVERY PLATFORM FOR ROBUST HUMORAL AND CELLULAR IMMUNE RESPONSES - The present invention relates to a probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides. Probiotic-derived vesicles displaying this fusion protein as well as methods of inducing an immune response using the probiotic cells or vesicles are also disclosed. | 02-26-2015 |
20150064215 | THERAPEUTIC DELIVERY AND EXPRESSION SYSTEM, METHODS AND USES THEREOF - Therapeutic methods for cancer treatments using a combined prokaryotic-eukaryotic delivery and expression system for the delivery of multiple therapeutic factors via a modified tumor-targeted bacteria. A targeted bacteria-vector system elicits an inter-kingdom dual expression (IKDE) of antitumor agents, in the nucleus or cytoplasm of eukaryotic cells, with priming and maintenance of the vector in the bacterium. The therapeutic factors include small interfering RNAs, tumoricidal proteins, DNA molecules, or a combination thereof. The system provides direct killing of tumor cells and alters the tumor microenvironment by expressing anti-angiogenic factors and cytokines in intracellular and/or extracellular environments. Also provided are methods of using natural exosomes comprising cargoes obtained from the bacterially infected cells. The bacteria-vector system is useful for many types of tumor and cancer as well as recombinant vaccines. The method causes significant regression of tumor and prolongs survival of tumor-bearing mice and subject without detectable systemic toxicity. | 03-05-2015 |
20150098964 | SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING LISTERIA VACCINE TREATMENT - This invention provides methods and compositions for using a live attenuated | 04-09-2015 |
20150125485 | METHODS AND COMPOSITIONS USING LISTERIA FOR ENHANCING IMMUNOGENICITY BY PRIME BOOST - Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active | 05-07-2015 |
20150140032 | VACCINE - The present invention is based on the finding that microorganisms can be modified so as to express certain factors important in generating or raising host immune responses. In particular, the invention provides modified microorganisms which, when subjected to conditions which would be expected to suppress or reduce the expression, function and/or activity of certain factors, exhibit increased (often significantly increased) expression, function and/or activity of those factors. The invention provides a modified microorganism capable of expressing at least one factor under conditions in which a wild-type (or unmodified) strain of the same microorganism, exhibits inhibited expression of the at least one factor. | 05-21-2015 |
20150297645 | CYCLIC DI-AMP INDUCTION OF TYPE I INTERFERON - Methods of modulating type-I interferon production in a cell are provided. | 10-22-2015 |
20150297702 | COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS - This invention provides compositions and methods for treating and vaccinating against a Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a human subject. | 10-22-2015 |
20150343045 | VACCINES FOR CONTROL OF EPIDEMIC AEROMONAS HYDROPHILA GENERATED BY MARKERLESS GENE DELETION - Disclosed are attenuated bacteria, compositions comprising attenuated bacteria, and vectors and methods for preparing attenuated bacteria. The attenuated bacteria may include attenuated | 12-03-2015 |
20150343048 | AN ATTENUATED EHEC AND CLOSTRIDIAL TOXINS TCDA AND TCDB BASED VACCINE FOR CLOSTRIDIUM DIFFICIL ASSOCIATED DISEASE (CDAD) - Provided are novel methods for expressing antigens in a vaccine vector strain, a live oral vaccine designed to prevent clostridium difficile-associated disease and methods for delivering antigens to the mucosal immune system of a subject. | 12-03-2015 |
20150366955 | COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS - This invention provides compositions and methods for treating and vaccinating against a Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a non-human animal. | 12-24-2015 |
20150368654 | MODIFIED LISTERIA BACTERIA AND USES THEREOF | 12-24-2015 |
20160015798 | ATTENUATED CHLAMYDIA VACCINE - The invention provides vectors, attenuated pathogens, compositions, methods, and kits for use in preventing or treating infection by an infectious pathogen, especially | 01-21-2016 |
20160101168 | ATTENUATED SALMONELLA BACTERIA AND METHODS OF USING - Provided herein are attenuated | 04-14-2016 |
20160175415 | METHODS AND COMPOSITIONS USING LISTERIA FOR ENHANCING IMMUNOGENICITY BY PRIME BOOST | 06-23-2016 |
20160199467 | REGULATED EXPRESSION OF ANTIGEN AND/OR REGULATED ATTENTUATION TO ENHANCE VACCINE IMMUNOGENICITY AND/OR SAFETY | 07-14-2016 |